Your browser doesn't support javascript.
loading
Efficiency of CMV serodiagnosis during pregnancy in daily laboratory routine.
Müller, Jens; Flindt, Juliane; Pollmann, Marc; Saschenbrecker, Sandra; Borchardt-Lohölter, Viola; Warnecke, Jens M.
Afiliação
  • Müller J; Limbach Labor MVZ Westmecklenburg GbR, Department of Infection Serology, Schwerin, Germany.
  • Flindt J; Limbach Labor MVZ Westmecklenburg GbR, Department of Infection Serology, Schwerin, Germany.
  • Pollmann M; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.
  • Saschenbrecker S; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.
  • Borchardt-Lohölter V; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany. Electronic address: v.borchardt-lohoelter@euroimmun.de.
  • Warnecke JM; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.
J Virol Methods ; 314: 114685, 2023 04.
Article em En | MEDLINE | ID: mdl-36709885
ABSTRACT

BACKGROUND:

Maternal acute primary cytomegalovirus (CMV) infection during the first trimester may cause severe long-term sequelae in newborns. For risk assessment, serological screening is routinely performed in pregnant women based on IgM, IgG and avidity tests using whole-virus antigen. A recent study evaluated the diagnostic value of recombinant protein-based ELISAs as second-line tests in pregnancy CMV screening, including anti-p52 IgM and anti-gB IgG as markers defining the early and late phase of infection, respectively. In the present study, these recombinant ELISAs were used as first-line screening tests in daily laboratory routine and compared to lysate-based assays with respect to [i] the number of conclusive results obtained with the initial sample and [ii] the underlying workload.

METHODS:

553 unselected routine serum samples from pregnant women were tested for anti-CMV IgM and IgG antibodies using lysate-based ELISAs and avidity testing. Anti-CMV IgM antibodies against recombinant p52 and anti-CMV IgG antibodies against recombinant glycoprotein B (gB) were also determined by ELISA. All assays were performed and interpreted according to the manufacturer's instructions.

RESULTS:

For lysate-based IgM, IgG and avidity testing, 84.6 % of samples yielded conclusive results in a total of 1156 tests, while 15.4 % needed follow-up testing of a consecutive sample. Anti-p52 CMV IgM and anti-gB CMV IgG testing produced conclusive results for 92.8 % of samples in a total of 1026 tests, while 7.2 % samples required follow-up testing.

CONCLUSIONS:

The first-line use of ELISAs measuring anti-p52 CMV IgM and anti-gB CMV IgG antibodies to test for maternal CMV infection increases the number of conclusive results derived from an initial serum sample while requiring a considerably lower number of tests compared to the lysate-based approach. For day-to-day routines in a diagnostic laboratory, this high efficiency of the recombinant testing approach has significant practical relevance.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Infecciosas na Gravidez / Infecções por Citomegalovirus Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Female / Humans / Newborn / Pregnancy Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Infecciosas na Gravidez / Infecções por Citomegalovirus Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Female / Humans / Newborn / Pregnancy Idioma: En Ano de publicação: 2023 Tipo de documento: Article